The Institute F_AO1_R Clinical AH0_N_D Economic Review    ICER    IH1_Z AH0 Boston B_EY1_S_T IH2_N_D_IH0_P_EH1_N_D_AH0_N_T N_AA0_N_P_R_AA1_F_AH0_T AO2_R_G_AH0_N_AH0_Z_EY1_SH_AH0_N DH_AE1_T S_IY1_K_S T_UW1 IH2_M_P_R_UW1_V HH_EH1_L_TH_K_EH2_R V_AE1_L_Y_UW0 B_AY1 P_R_AH0_V_AY1_D_IH0_NG K_AA2_M_P_R_IY0_HH_EH1_N_S_IH0_V K_L_IH1_N_AH0_K_AH0_L AH0_N_D K_AA1_S_T IH0_F_EH1_K_T_IH0_V_N_AH0_S AE0_N_AE1_L_IH0_S_IY2_Z AH1_V T_R_IY1_T_M_AH0_N_T_S    T_EH1_S_T_S    AH0_N_D P_R_AH0_S_IY1_JH_ER0_Z    It W_AA1_Z F_AW1_N_D_IH0_D IH0_N AH0_B_AW1_T 2005 B_AY1 F_AH0_Z_IH1_SH_AH0_N R_IY1_S_ER0_CH_ER0 Steven Pearson    MD    MSc    FRCP    Until 2014 IH1_T K_AA1_N_S_AH0_N_T_R_EY2_T_AH0_D AA1_N AH0_S_EH1_S_IH0_NG HH_EH1_L_TH K_EH1_R K_AA1_S_T_S    R_AE1_DH_ER0 DH_AE1_N IH0_V_AE1_L_Y_UW0_EY2_T_IH0_NG D_R_AH1_G_Z    It IH0_V_AE1_L_Y_UW0_EY2_T_S DH_AH0 K_AA1_S_T IH0_F_EH1_K_T_IH0_V_N_AH0_S AH1_V D_R_AH1_G_Z IH0_N AH0 S_IH1_M_AH0_L_ER0 W_EY1 T_UW1 DH_AH0 UK EH1_S NICE      AH0_N_D HH_AE1_Z K_AH1_M AH1_N_D_ER0 S_AH1_M K_R_IH1_T_IH0_S_IH2_Z_AH0_M F_R_AH1_M DH_AH0 D_R_AH1_G IH1_N_D_AH0_S_T_R_IY0    It HH_AE1_Z IH1_SH_UW0_D AH0 N_AH1_M_B_ER0 AH1_V D_R_AH1_G IH0_V_AE2_L_Y_UW0_EY1_SH_AH0_N_Z S_IH1_N_S 2014    AH0_S_P_EH1_SH_L_IY0 S_IH1_N_S July 2015     The IH2_N_S_T_IH0_T_UW1_SH_AH0_N IH1_Z F_AH1_N_D_AH0_D B_AY1 DH_AH0 Laura AH0_N_D John Arnold Foundation    D_R_AH1_G M_EY1_K_ER0_Z    IH2_N_SH_UH1_R_ER0_Z    AH0_N_D G_AH1_V_ER0_N_M_AH0_N_T G_R_AE1_N_T_S    ICER EH1_S_T_AH0_M_AH0_T_S DH_AH0 AH0_M_AW1_N_T AH1_V M_AH1_N_IY0 AH0_V_EY1_L_AH0_B_AH0_L T_UW1 B_IY1 S_P_EH1_N_T AE1_N_Y_UW0_AH0_L_IY0 AA1_N N_UW1 D_R_AH1_G_Z AH0_N_D DH_EH1_N D_IH0_V_AY1_D_Z DH_AE1_T AH0_M_AW1_N_T B_AY1 DH_AH0 N_AH1_M_B_ER0 AH1_V IH0_K_S_P_EH1_K_T_AH0_D US Food AH0_N_D Drug Administration AH0_P_R_UW1_V_AH0_L_Z T_UW1 S_EH1_T AE1_N AH0_F_AO2_R_D_AH0_B_IH1_L_AH0_T_IY0 B_EH1_N_CH_M_AA2_R_K    ICER EH1_S AH0_F_AO2_R_D_AH0_B_IH1_L_AH0_T_IY0 K_AE2_L_K_Y_AH0_L_EY1_SH_AH0_N_Z AH0_JH_AH1_S_T F_AO1_R D_R_AH1_G_Z T_AA1_R_G_AH0_T_IH0_NG P_R_EH1_V_AH0_L_AH0_N_T D_IH0_Z_IY1_Z_AH0_Z AH0_N_D AO1_R DH_OW1_Z P_R_IH0_Z_EH1_N_T_IH0_NG AH0 S_AH0_G_N_IH1_F_IH0_K_AH0_N_T K_L_IH1_N_AH0_K_AH0_L B_EH1_N_AH0_F_IH0_T B_AY1 S_EH1_T_IH0_NG DH_AH0 TH_R_EH1_SH_OW2_L_D AE1_T D_AH1_B_AH0_L DH_AH0 AH0_V_EY1_L_AH0_B_AH0_L F_AH1_N_D_Z D_IH0_V_AY1_D_IH0_D B_AY1 DH_AH0 IH0_K_S_P_EH1_K_T_AH0_D N_AH1_M_B_ER0 AH1_V N_UW1 D_R_AH1_G_Z    AH0_P_R_UW1_V_D B_AY1 FDA     After D_IH0_S_K_AH1_SH_AH0_N_Z IH0_N 2016 ICER B_R_AO1_D_AH0_N_D IH1_T_S K_W_AA1_L_AH0_T_IY0 AH0_JH_AH1_S_T_IH0_D L_AY1_F Y_IH1_R TH_R_EH1_SH_OW2_L_D T_UW1  $ 50 000  - $ 150 000    It IH1_SH_UW0_D AH0 D_R_AE1_F_T R_IY0_P_AO1_R_T DH_AE1_T S_EH1_D Sovaldi wasn T_IY1 W_ER1_TH DH_AH0 L_IH1_S_T P_R_AY1_S AH1_V AH0_B_AW1_T  $ 84 000 AH0 Y_IH1_R    As AH1_V May 2016 ICER P_AH1_B_L_IH0_SH_T F_AY1_N_AH0_L R_IH0_P_AO1_R_T_S AA1_N  -  Multiple myeloma  -  Palliative K_EH1_R    It HH_AE1_Z criticised DH_AH0 HH_AY1 P_R_AY1_S AH1_V D_R_AH1_G_Z F_AO1_R AO2_S_T_IY0_AA2_P_ER0_OW1_S_IH0_S    M_AH1_L_T_AH0_P_AH0_L S_K_L_ER0_OW1_S_AH0_S    PCSK9 K_AH0_L_EH1_S_T_ER0_AO2_L meds    AH0_N_D IH2_M_Y_UW1_N_OW0 AA0_NG_K_AA1_L_AH0_JH_IY0 TH_EH1_R_AH0_P_IY0_Z     In 2017 IH1_T IH1_SH_UW0_D AH0 K_AA2_N_T_R_AH0_V_ER1_SH_AH0_L D_R_AE1_F_T R_IY0_P_AO1_R_T AA1_N PARP IH2_N_HH_IH1_B_AH0_T_ER0_Z F_AO1_R OW0_V_EH1_R_IY2_AH0_N K_AE1_N_S_ER0    P_R_IH0_L_IH1_M_AH0_N_EH2_R_IY0 L_IH1_S_T AH1_V D_R_AH1_G_Z T_UW1 B_IY1 IH0_V_AE1_L_Y_UW0_EY2_T_AH0_D IH2_N_K_L_UW1_D_Z rociletinib    AZD 9291    necitumumab    nivolumab    AH0_N_D pembrolizumab F_AO1_R S_M_AO1_L S_EH1_L L_AH1_NG K_AE1_N_S_ER0 ;  fingolimod    dimethyl fumarate    teriflunomide    alemtuzumab    AH0_N_D daclizumab F_AO1_R M_AH1_L_T_AH0_P_AH0_L S_K_L_ER0_OW1_S_AH0_S ;  AH0_N_D ixekizumab AH0_N_D brodalumab F_AO1_R S_ER0_AY1_AH0_S_AH0_S AO1_R psoriatic AA0_R_TH_R_AY1_T_AH0_S    